0.35 (2.25%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Neutral
Earnings
Weak
Earnings
Very Weak
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Aurinia Pharmaceuticals Inc.
Telephone
1.250.744.2487
Address
Suite 140, 14315–118 Avenue, Edmonton, AB T5L 4S6
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 7.28 - 16.88
Trade Value (12mth)
US$4,786,781.00
1 week
1.77%
1 month
-1.71%
YTD
1.3%
1 year
86.45%
All time high
33.97
EPS 3 yr Growth
-380.40%
EBITDA Margin
47.90%
Operating Cashflow
$136m
Free Cash Flow Return
25.10%
ROIC
53.20%
Interest Coverage
31.30
Quick Ratio
4.80
Shares Outstanding (Fully Diluted)
138m
HALO Sector
Healthcare
Next Company Report Date
04-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 11 May 26 | |
| 11 May 26 | |
| 07 May 26 | |
| 07 May 26 | |
| 07 May 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -0.54 | 0.04 | 2.14 | | | | ||
EPS (Fully Diluted) | $ | | | | | -0.54 | 0.04 | 2.07 | | | | ||
Growth | % | | | | | 28.5 | 107.4 | 5,216.9 | | | | ||
PE | X | | | | | N/A | 228.5 | 7.7 | | | | ||
EV/EBITDA | X | | | | | N/A | 30.6 | 13.9 | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
